FDG PET/CT评估紫杉醇-雷莫西尤单抗治疗转移性胃食管交界癌的完全代谢缓解
本文报告2例不同HER2生物标志物特征的转移性胃食管交界癌患者,在接受紫杉醇-雷莫西尤单抗二线治疗后,FDG PET/CT评估显示完全代谢缓解。作者指出FDG PET/CT是评估转移性胃食管交界癌靶向药物治疗反应的有用方法。
要点
- 紫杉醇-雷莫西尤单抗用于铂类-5-FU化疗进展后的转移性胃食管交界癌二线治疗。
- 文献报道该方案治疗后常见反应仅为部分缓解,完全代谢缓解罕见。
- FDG PET/CT可用于评估转移性胃食管交界癌靶向药物的治疗反应。
核心结论
- FDG PET/CT是评估转移性胃食管交界癌靶向药物治疗反应的有用方法。
研究设计与样本
- 本文为病例报告,报告2例接受紫杉醇-雷莫西尤单抗治疗的转移性胃食管交界癌患者,HER2生物标志物特征不同。
主要发现
- 2例转移性胃食管交界癌患者经紫杉醇-雷莫西尤单抗治疗后,FDG PET/CT评估均显示完全代谢缓解。
- 既往仅有1例来自RAINBOW试验的病例报告显示治疗后FDG PET/CT阴性,但缺乏基线检查。
临床怎么用
- 在转移性胃食管交界癌靶向治疗中,可考虑使用FDG PET/CT进行疗效评估。
局限性
- 本文仅为2例病例报告,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Paclitaxel-ramucirumab chemotherapy is indicated in second line of metastatic gastroesophageal junction cancer (mGEJC) after progression under platinum-5-FU chemotherapy. Nevertheless, the reported common response after treatment is only partial within series. To date, only 1 case report of negative posttreatment FDG PET/CT was published without baseline examination from RAINBOW trial. We illustrated the interest of FDG PET/CT to evaluate treatment especially paclitaxel-ramucirumab with 2 examples of complete metabolic responses in 2 patients having different HER2 biomarker profiles of mGEJC. As illustrated, FDG PET/CT emerges as a useful approach for therapeutic assessment of targeted drugs in mGEJC.
引用
- Amrane K, Querellou S, Schick U, et al. Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer. Clin Nucl Med. 2020. PMID: 31876811. doi:10.1097/RLU.0000000000002882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。